GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc., a clinical stage biopharmaceutical company developing Chrysalin as a Medical Countermeasure and for the treatment of Acute Respiratory Distress Syndrome (ARDS), announced today that it…
GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego. “Based on preclinical…
GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung…
GALVESTON An island biopharmaceutical company has received U.S. Food and Drug Administration clearance for its first ever human tests of a drug to treat a potentially fatal lung condition that…
By MYER LEE The Daily News Dec 13, 2020 Darrell Carney’s company, Chrysalis BioTheraputics, received $10.4 million to continue developing TP508, a drug that remedies the effects of radiation exposure. …
December 01, 2020 09:10 AM Eastern Standard Time GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that…
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular…
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure, announced today that the National Institute of Allergy and Infectious…
GALVESTON A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to a $1.5 million grant from…
GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services'…
We answer all email and requests as they come in. If you have an urgent matter or would like to place an order please click the link below to give us a call.
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.